{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T17:56:37Z","timestamp":1764784597773},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,20]]},"DOI":"10.7759\/cureus.14589","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T17:55:46Z","timestamp":1618941346000},"source":"Crossref","is-referenced-by-count":2,"title":["Vertebral Osteomyelitis Secondary to Bacillus Calmette-Gu\u00e9rin Instillation Therapy for Transitional Cell Carcinoma In Situ"],"prefix":"10.7759","author":[{"given":"Tariq M","family":"Jaber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Samiullah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Surti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Bladder cancer statistics. (2018). Accessed. February 24, 2021: https:\/\/www.wcrf.org\/dietandcancer\/cancer-trends\/bladder-cancer-statistics."},{"key":"ref2","unstructured":"Diagnosis and treatment of non-muscle invasive bladder cancer. AUA\/SUO Joint Guideline (2020). (2020). Accessed: February 24, 2021: https:\/\/www.auanet.org\/guidelines\/bladder-cancer-non-muscle-invasive-guideline."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110393","article-title":"Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect","volume":"129","author":"Han J","year":"2020","unstructured":"Han J, Gu X, Li Y, Wu Q. Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect. Biomed Pharmacother. 2020, 129:110393. 10.1016\/j.biopha.2020.110393","journal-title":"Biomed Pharmacother"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4103\/2152-7806.89879","article-title":"Mycobacterium bovis spondylodiscitis after intravesical Bacillus Calmette-Gu\u00e9rin therapy","volume":"2","author":"Obaid S","year":"2011","unstructured":"Obaid S, Weil AG, Rahme R, Gendron C, Shedid D. Mycobacterium bovis spondylodiscitis after intravesical Bacillus Calmette-Gu\u00e9rin therapy. Surg Neurol Int. 2011, 2:162. 10.4103\/2152-7806.89879","journal-title":"Surg Neurol Int"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2011.000480","article-title":"Adjuvant intravesical bacillus Calmette-Gu\u00e9rin therapy and survival among elderly patients with non-muscle-invasive bladder cancer","volume":"9","author":"Spencer BA","year":"2013","unstructured":"Spencer BA, McBride RB, Hershman DL, et al.. Adjuvant intravesical bacillus Calmette-Gu\u00e9rin therapy and survival among elderly patients with non-muscle-invasive bladder cancer. J Oncol Pract. 2013, 9:92-8. 10.1200\/JOP.2011.000480","journal-title":"J Oncol Pract"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001986","article-title":"Intravesical bacillus Calmette-Guerin in Ta and T1 bladder cancer","volume":"2000","author":"Shelley MD","year":"2000","unstructured":"Shelley MD, Court JB, Kynaston H, Wilt TJ, Fish RG, Mason M. Intravesical bacillus Calmette-Guerin in Ta and T1 bladder cancer. Cochrane Database Syst Rev. 2000, 2000:CD001986. 10.1002\/14651858.CD001986","journal-title":"Cochrane Database Syst Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1086\/314064","article-title":"Efficacy and safety of bacille Calmette-Gu\u00e9rin immunotherapy in superficial bladder cancer","volume":"31","author":"Lamm DL","year":"2000","unstructured":"Lamm DL. Efficacy and safety of bacille Calmette-Gu\u00e9rin immunotherapy in superficial bladder cancer. Clin Infect Dis. 2000, 31:S86-90. 10.1086\/314064","journal-title":"Clin Infect Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.545","article-title":"Mycobacterial osteomyelitis of the spine following intravesical BCG therapy for bladder cancer","volume":"8","author":"Mackel CE","year":"2016","unstructured":"Mackel CE, Burke SM, Huhta T, Riesenburger R, Weller SJ. Mycobacterial osteomyelitis of the spine following intravesical BCG therapy for bladder cancer. Cureus. 2016, 8:e545. 10.7759\/cureus.545","journal-title":"Cureus"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4137\/CCRep.S39904","article-title":"Disseminated Mycobacterium bovis infection complicating intravesical BCG instillation for the treatment of superficial transitional cell carcinoma of the bladder","volume":"9","author":"Elzein F","year":"2016","unstructured":"Elzein F, Albogami N, Saad M, El Tayeb N, Alghamdi A, Elyamany G. Disseminated Mycobacterium bovis infection complicating intravesical BCG instillation for the treatment of superficial transitional cell carcinoma of the bladder. Clin Med Insights Case Rep. 2016, 9:71-3. 10.4137\/CCRep.S39904","journal-title":"Clin Med Insights Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01714-07","article-title":"Mycobacterium bovis BCG vertebral osteomyelitis after intravesical BCG therapy, diagnosed by PCR-based genomic deletion analysis","volume":"45","author":"Nikaido T","year":"2007","unstructured":"Nikaido T, Ishibashi K, Otani K, et al.. Mycobacterium bovis BCG vertebral osteomyelitis after intravesical BCG therapy, diagnosed by PCR-based genomic deletion analysis. J Clin Microbiol. 2007, 45:4085-7. 10.1128\/JCM.01714-07","journal-title":"J Clin Microbiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000119","article-title":"Bacillus Calmette-Gu\u00e9rin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature","volume":"93","author":"P\u00e9rez-Jacoiste As\u00edn MA","year":"2014","unstructured":"P\u00e9rez-Jacoiste As\u00edn MA, Fern\u00e1ndez-Ruiz M, L\u00f3pez-Medrano F, et al.. Bacillus Calmette-Gu\u00e9rin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature. Medicine (Baltimore). 2014, 93:236-54. 10.1097\/MD.0000000000000119","journal-title":"Medicine (Baltimore)"},{"key":"ref12","unstructured":"Centers For Disease Control and Prevention. Mycobacterium bovis (bovine tuberculosis) in humans. (2012). Accessed: February 24, 2021: https:\/\/www.cdc.gov\/tb\/publications\/factsheets\/general\/mbovis.htm."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1179\/2045772311Y.0000000023","article-title":"Spinal tuberculosis: a review","volume":"34","author":"Garg RK","year":"2011","unstructured":"Garg RK, Somvanshi DS. Spinal tuberculosis: a review. J Spinal Cord Med. 2011, 34:440-54. 10.1179\/2045772311Y.0000000023","journal-title":"J Spinal Cord Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4988-z","article-title":"Low-dose bacillus Calmette-Guerin versus full-dose for intermediate and high-risk of non-muscle invasive bladder cancer: a Markov model","volume":"18","author":"Wang Z","year":"2018","unstructured":"Wang Z, Xiao H, Wei G, et al.. Low-dose bacillus Calmette-Guerin versus full-dose for intermediate and high-risk of non-muscle invasive bladder cancer: a Markov model. BMC Cancer. 2018, 18:1108. 10.1186\/s12885-018-4988-z","journal-title":"BMC Cancer"},{"key":"ref15","unstructured":"Intravesical administration of therapeutic medication for the treatment of bladder cancer. (2020). Accessed. February 24, 2021: https:\/\/www.auanet.org\/guidelines\/intravesical-administration-of-therapeutic-medication."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2018.02.045","article-title":"Maintenance versus non-maintenance intravesical bacillus Calmette-Guerin instillation for non-muscle invasive bladder cancer: A systematic review and meta-analysis of randomized clinical trials","volume":"52","author":"Chen S","year":"2018","unstructured":"Chen S, Zhang N, Shao J, Wang X. Maintenance versus non-maintenance intravesical bacillus Calmette-Guerin instillation for non-muscle invasive bladder cancer: A systematic review and meta-analysis of randomized clinical trials. Int J Surg. 2018, 52:248-57. 10.1016\/j.ijsu.2018.02.045","journal-title":"Int J Surg"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.11.073","article-title":"The dose-response relationship of bacillus Calmette-Gu\u00e9rin and urothelial carcinoma cell biology","volume":"195","author":"Shah G","year":"2016","unstructured":"Shah G, Zhang G, Chen F, Cao Y, Kalyanaraman B, See WA. The dose-response relationship of bacillus Calmette-Gu\u00e9rin and urothelial carcinoma cell biology. J Urol. 2016, 195:1903-10. 10.1016\/j.juro.2015.11.073","journal-title":"J Urol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.21037\/tcr.2017.02.04","article-title":"High dose bacillus Calmette-Guerin (BCG) for urothelial carcinoma is trickier than expected","volume":"6","author":"Siddiqui MR","year":"2017","unstructured":"Siddiqui MR, Agarwal PK. High dose bacillus Calmette-Guerin (BCG) for urothelial carcinoma is trickier than expected. Transl Cancer Res. 2017, 6:31-2. 10.21037\/tcr.2017.02.04","journal-title":"Transl Cancer Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000103100.22951.5e","article-title":"Efficacy of office fulguration for recurrent low grade papillary bladder tumors less than 0.5 cm","volume":"171","author":"Donat SM","year":"2004","unstructured":"Donat SM, North A, Dalbagni G, Herr HW. Efficacy of office fulguration for recurrent low grade papillary bladder tumors less than 0.5 cm. J Urol. 2004, 171:636-9. 10.1097\/01.ju.0000103100.22951.5e","journal-title":"J Urol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/53901-vertebral-osteomyelitis-secondary-to-bacillus-calmette-gurin-instillation-therapy-for-transitional-cell-carcinoma-in-situ","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:32:11Z","timestamp":1707507131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/53901-vertebral-osteomyelitis-secondary-to-bacillus-calmette-gurin-instillation-therapy-for-transitional-cell-carcinoma-in-situ"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,20]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.14589","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4,20]]}}}